Protagen Working With MATURA Consortium to Develop Proteomic Test to Predict Drug Response in RA | GenomeWeb

NEW YORK (GenomeWeb) – Protein diagnostics firm Protagen has joined the UK-based Maximising Therapeutic Utility for Rheumatoid Arthritis (MATURA) consortium, through which it aims to develop a test for predicting patient response to therapy in RA.

The company hopes via its participation in the consortium to identify a subset of predictive markers from a current panel of 100 proteins it identified as possibly useful through previous studies of RA, Georg Lautscham, the company's chief business officer, told GenomeWeb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: a sequencing-based screen of Lyme disease-causing pathogen, the range of animals bitten by Anopheles darling mosquitoes in Peru, and more.

An NC State researcher is exploring the use of CRISPR-Cas3 as an anti-microbial, Gizmodo reports.

The Earth BioGenome Project plans to sequence all life on Earth, according to ScienceInsider.

For those who are concerned about Trump administration actions related to science, a new column in Scientific American has suggestions for ways to fight back.